东菱克栓酶联合蚓激酶及阿司匹林治疗进展性脑梗死的疗效观察

目的评价东菱克栓酶联合蚓激酶及阿司匹林治疗进展性脑梗死的疗效,为临床治疗提供依据。方法对2003年初至2006年12月我院54例急性进展性脑梗死分组治疗前后的血小板、凝血酶原时间、纤维蛋白原定量及神经功能缺损评分变化进行疗效评估。结果治疗组神经功能缺损评分明显优于对照组(P<0.01),血小板、凝血酶原时间在治疗前后比较无显著性差异(P>0.05),纤维蛋白原定量治疗后下降明显,特别是3～5d时,有显著性差异(P<0.01)。结论东菱克栓酶联合蚓激酶、阿司匹林治疗进展性脑梗死同蚓激酶、阿司匹林联合治疗相比较,治疗后神经功能缺损评分2组均有显著性改善,组间比较神经功能缺损评分治疗组明显优于对照组。

Curative observation on batroxobin associated with lumbrukinase and aspirin to treat progressive cerebral infarction

Objective To evaluate the curative effect by batroxobin associated with lumbrukinase and aspirin to treat progressive cerebral infarction in order to provide basis for clinical therapy.Methods From early 2003 to December 2006,54 cases of acute progresive cerebral infarction were selected and divided into two groups:batroxobin associated with lumbrukinase and aspirine(therapy group),lumbrukinase associated with aspirine(control group);detecting platelet,prothrombin time,fibrinogen quantitation and neurologic impairment score before and after therapy to measure curative effect.Results In therapy group neurologic impairment score has more obvious advantage than that in control group(P<0.01).Platelet and prothrombin time have no significant difference before and affer therapy(P>0.05),but fibrinogen quantitation has decreased obviously after therapy especially in the first 3 to 5 days(P<0.01)in therapy group.Conclusions The neurologic impairment score of the two groups both have significant improvement,but after therapy neurologic impairment acore more obvious advantage in therakpy group than that in control group.